About this trial
For continuous variables, mean, median, minimum, and maximum will be used for the descriptive purpose. For categorical variables, frequency and percentage will be used for descriptive statistics. The variables of OS will be estimated by the Kaplan-Meier method. Differences between groups will be calculated using the log-rank test for univariate analysis. Cox's proportional hazards model will be employed to test independent prognostic factors. All calculations will be performed using the Statistical Package of Social Sciences software, version 17.0 (SPSS, Inc., Chicago, IL, USA). The level of statistical significance will be set at 0.05 for all tests.
Eligibility criteria
Qualifiers
Patients with relapsed/refractory CD20+ diffuse large B-cell lymphoma.
Age greater than 20 years and younger than 75 years old.
Measurable disease
Patients must have an ECOG performance status of less than or equal to 2.
Disqualifiers
Patients who have prior treatment with ruxolitinib or taxane for DLBCL.
Pregnant or breast-feeding females.
Active or uncontrolled infection.
Life expectancy < 6 months
Trial design
Treatments tested in this trial
- Rituximab Paclitaxel Ruxolitinib
Treatment groups
Locations
Sponsors and collaborators
National Health Research Institutes, Taiwan
Lead sponsor
Taipei Veterans General Hospital, Taiwan
Collaborator
Chang Gung Memorial Hospital
Collaborator
China Medical University Hospital
Collaborator
Shin Kong Wu Huo-Shih Memorial Hospital
Collaborator